

**FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH (FNLCR)
INSTITUTIONAL BIOSAFETY COMMITTEE
MINUTES**

NOVEMBER 20, 2012

CALL TO ORDER / ANNOUNCEMENTS

The FNLCR Institutional Biosafety Committee was convened at 12:10 p.m. in Building 549 Executive Board Room with the following members in attendance:

Voting (Quorum = 9)

- | | |
|---|--|
| <input checked="" type="checkbox"/> Michael Baseler | <input type="checkbox"/> Sarah Hooper (regrets) |
| <input checked="" type="checkbox"/> Theresa Bell | <input checked="" type="checkbox"/> Bhargavi Kondragunta |
| <input checked="" type="checkbox"/> Rev. David Betzner (arrived at 12:15pm) | <input type="checkbox"/> Serguei Kozlov (regrets) |
| <input checked="" type="checkbox"/> Stephen Creekmore | <input checked="" type="checkbox"/> Dan McVicar (Chair) |
| <input type="checkbox"/> Bruce Crise (regrets) | <input checked="" type="checkbox"/> Randall Morin |
| <input checked="" type="checkbox"/> Eric Freed | <input type="checkbox"/> Shalini Oberdoerffer (regrets) |
| <input checked="" type="checkbox"/> Melinda Hollingshead | <input checked="" type="checkbox"/> Raja Sriperumbudur |
| <input type="checkbox"/> Stephen Hughes (regrets) | <input checked="" type="checkbox"/> Lucien Winegar |

Non-Voting

- Walter Hubert
 Kim DiGiandomenico

APPROVAL OF MINUTES FROM OCTOBER 16, 2012 MEETING

The minutes from the October 16, 2012 meeting were approved as written. A motion and second were made. (For: 11; Against: 0; Abstain: 0)

ACCIDENT REVIEWS

There was one OBA reportable needlestick that occurred between the October and November IBC meetings. A new employee was training on a new piece of equipment, the Bioject system, which is a needle-less delivery system. After drawing up the construct from the dilution vial using a needle and syringe, the employee misinterpreted the directions and was attempting to remove air bubbles from the syringe when the needlestick occurred.

REVIEW OF PROTOCOLS

NEW REGISTRATIONS

Richard Hodes 12-78: Overexpression of a Vgamma2-Cbeta2 hybrid T cell receptor chain in BM cells for transplantation to assess immune-competence The goal of this project is to learn the specificity and function of a novel T cell receptor (TCR) chain encoded by trans-rearrangement between the TCR-gamma locus on chromosome 13 and the TCR-beta locus on chromosome 6. Murine cells will be transduced with ecotropic murine retrovirus in Bethesda and then sent to Frederick for injection into animals. The committee requested some additional clarification on the parental 'backbones' used to make the viral vector as well as had some minor edits to the SOP. Melinda Hollingshead moved to approve the registry. Theresa Bell seconded the motion. For: 11; Against: 0; Abstain: 0

FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH (FNLCR)

INSTITUTIONAL BIOSAFETY COMMITTEE

MINUTES

NOVEMBER 20, 2012

Robert Wiltrout 12-79: Infection of mice with Encephalomyocarditis virus (EMCV) At November meeting, the IBC chairman informed the committee that this registration had been put on hold. The lab requested to meet with EHS-Biosafety to further discuss the safety requirements for working with the agent and would then conduct a cost analysis to see if they would move forward with the research.

David Roberts 12-80: Cross-talk between antiogenesis genes and nutritional agents in carcinogenesis Notification to committee *Breeding Only*

RENEWALS

Ying Zhang 12-81: TGF-beta/Smad signaling The goal of this renewal is to understand the role of TGF-beta, its downstream regulators in tumorigenesis (Smurfs) and cancer metastasis. We will use cell lines that overexpress either cDNA or shRNA of Smurfs. These cell lines are/will be established using a retroviral delivery system. It is based on Moloney Murine Leukemia Virus (MoMuLV) or Murine Stem Cell Virus (MSCV) and allows for delivery of genes to most dividing mammalian cell types. All transductions will occur in Bethesda; only transduced cells will be manipulated in Frederick by the LASP staff. During the pre-review, there was correspondence with the PI regarding complementation and recombination. The committee requested clarification on what materials would be sent back to Bethesda at the completion of the experiment. Eric Freed moved to approve the registry with the clarification. Mike Baseler seconded the motion. (Post-meeting note: PI clarified that both mice and fixed/unfixed organs would be transported back to Bethesda). For: 11; Against: 0; Abstain: 0

Ron Hornung 12-82: Chronic Epstein-Barr Virus Protocols This renewal is a continuation of ongoing work in this lab. The responsibility of the Immunological Monitoring Laboratory (IML) in this EBV protocol is to accumulate and safely store, plasma and PBMCs for a well-characterized cohort of patients with chronic EBV virus infection. Upon request, the IML will ship the plasma and cell samples to allow for the determination of antibody levels and persistence of EBV viral load in these patients after therapy. The lead reviewers felt that the SOPs adequately addressed the hazards of handling the materials involved; however, it was requested for the following clarifying statement to be added in Part A3 - Because the samples are coming from immunosuppressed patients, there could be more than just EBV in the samples. Additionally the committee strongly recommended that lab staff be offered an EBV titer prior to initiating the work in the event that they have never been exposed to EBV. A positive or negative titer would not preclude them from doing the work; however would be good information to have should an occupational exposure occur (an adult has a more severe response to EBV infection than a younger individual so earlier treatment would be critical should an exposure occur). Steve Creekmore moved to approve the registration with the aforementioned clarification and recommendation. Theresa Bell seconded the motion. For: 11; Against: 0; Abstain: 0

OUTSTANDING ITEMS

John Gilly 12-67: Production of chimpanzee adenoviral vectors for use as HIV vaccines Originally deferred at September meeting for further clarification on the adenoviral vector being used and support for the claim that it does not recombine, a description of the assay used to test for RCA and to what titer, clarification on how the virus stock is concentrated, where the QC testing is being done and why closed containment devices are not being used. October meeting – deferral continued for additional clarifications on adenoviral system being used. PI added additional

FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH (FNLCR)

INSTITUTIONAL BIOSAFETY COMMITTEE

MINUTES

NOVEMBER 20, 2012

clarifications to registry after the last IBC meeting; however, the committee recommended the following:

1. Restate the following from Part A3 in Part B5f1: *All activities performed at the VPP under this registration will assume that the chimp adenovector particles being handled are 100% infective (i.e., 100% replication competent) and will not be handled any differently than human adenovirus.*);
2. Include a statement at the end of B5f1 regarding the references/citations are for human adeno vectors, not chimp: *(NOTE: There is limited information on chimp Adenoviral vectors; however the above references are provided for human adenoviral vectors);*
3. Confirm that RCA testing includes 'hot' virus as a control – *This was confirmed in the Vitrology SOP (Section 8.2) after the meeting;*
4. Confirm how the SDS inactivation with boiling is verified; and
5. Schedule a mock observation of the procedures with EHS prior to going 'live'.

Theresa Bell moved to approve the registry pending aforementioned clarifications and mock observation. Randall Morin seconded the motion. For: 10; Against: 0; Abstain 1 (Bhargavi Kondragunta – works at VPP)

Dennis Klinman 12-71 (09-54): Infectious Pathogens used in the study of vaccines, adjuvants, and modulators of the innate immune system The purpose of the renewal is to continue ongoing research with three specific (vaccine strain) pathogens: Sterne strain anthrax, Francisella tularensis, and Listeria monocytogenes. In brief, the lab will vaccinate animals or treat them with agents known to improve and accelerate the induction of innate immunity, and evaluate whether these interventions (alone or in combination) reduce host susceptibility to pathogen challenge. There is the possibility that animal tissues may be isolated post-challenge to monitor pathogen load. The registry was deferred at the September meeting due to lack of response to pre-review questions; deferred at the October meeting for the lack of SOPs and some minor clarifications. November meeting - The committee requested additional clarification for the agents used in the pathogen challenge based on the detail provided in the animal protocol but that was lacking in the animal section of the IBC registry. Additionally, the committee requested clarification in the SOP, as the agents being used, although vaccine-strains, could still be infectious and elicit an immune response should an individual have an accidental exposure. The committee also requested a mock observation of the *in vitro* procedures, as training for the *in vivo* procedures in the specified animal facility had been completed by laboratory staff prior to the November meeting. Theresa Bell moved to conditionally approve the registry pending the aforementioned clarifications. Dan McVicar seconded the motion. For: 11; Against: 0; Abstain: 0

Ralph Parchment 12-75 (07-63): Specimens for Pharmacologic and Toxicologic Assessment Have not been able to release approval due to lack of signature sheets (PI out of country)

AMENDMENTS

Twenty-three amendments were processed and approved between the September and October IBC meetings.

FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH (FNLCR)

INSTITUTIONAL BIOSAFETY COMMITTEE

MINUTES

NOVEMBER 20, 2012

OTHER BUSINESS

- Progress on the web-to-database IBC registration was provided to the committee by Kim DiGiandomenico. In early December, the system would be made available to the committee and some scientist volunteers to beta-test.
- Changes to NIH Guidelines for Synthetic Nucleic Acid Molecules - effective date March 2013 – tabled
- Revisions to FNL IBC Charter were deferred for signature due to unresolved issues
- Membership – discussions were deferred regarding new membership until a later date

ADJOURNMENT

The meeting was adjourned at 1:25 pm.

Next meetings:

December 18, 2012

January 22, 2013